• Alexander SPH, Mathie A, Peters JA (2011). Guide to Receptors and Channels (GRAC), 5th Edition. Br J Pharmacol 164 (Suppl. 1): S1S324.
  • Bolognini D, Cascio MG, Ross RA, Pertwee RG (2010a). Conversion of AM630 into an apparent neutral CB2 receptor antagonist. Symposium on the Cannabinoids, International Cannabinoid Research Society, Research Triangle Park, NC, USA, P4–28.
  • Bolognini D, Costa B, Maione S, Comelli F, Marini P, Di Marzo V et al. (2010b). The plant cannabinoid Δ9-tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice. Br J Pharmacol 160: 677687.
  • Cheng Y-C, Prusoff WH (1973). Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22: 30993108.
  • Colquhoun D (1971). Lectures on Biostatistics. Oxford Univ Press: Oxford.
  • Gobeil F, Fortier A, Zhu T, Bossolasco M, Leduc M, Grandbois M et al. (2006). G-protein-coupled receptors signalling at the cell nucleus: an emerging paradigm. Can J Physiol Pharmacol 84: 287297.
  • Hall DA (2000). Modeling the functional effects of allosteric modulators at pharmacological receptors: an extension of the two-state model of receptor activation. Mol Pharmacol 58: 14121423.
  • Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA et al. (2002). International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54: 161202.
  • Kenakin T (1997). Pharmacologic Analysis of Drug-Receptor Interaction. Lippincott-Raven: Philadelphia, PA.
  • Kenakin T (2001). Inverse, protean, and ligand-selective agonism: matters of receptor conformation. FASEB J 15: 598611.
  • Leff P (1995). The two-state model of receptor activation. Trends Pharmacol Sci 16: 8997.
  • Lunn CA (2010). Updating the chemistry and biology of cannabinoid CB2 receptor-specific inverse agonists. Curr Top Med Chem 10: 768778.
  • Lunn CA, Reich E-P, Fine JS, Lavey B, Kozlowski JA, Hipkin RW et al. (2008). Biology and therapeutic potential of cannabinoid CB2 receptor inverse agonists. Br J Pharmacol 153: 226239.
  • Mancini I, Brusa R, Quadrato G, Foglia C, Scandroglio P, Silverman LS et al. (2009). Constitutive activity of cannabinoid-2 (CB2) receptors plays an essential role in the protean agonism of (+)AM1241 and L768242. Br J Pharmacol 158: 382391.
  • Pertwee RG (2005). Pharmacological actions of cannabinoids. In: Pertwee RG (ed.). Cannabinoids. Springer-Verlag: Heidelberg, pp. 151. Handbook Exp Pharmacol 168: 1–51.
  • Pertwee RG, Ross RA, Craib SJ, Thomas A (2002). (-)-Cannabidiol antagonizes cannabinoid receptor agonists and noradrenaline in the mouse vas deferens. Eur J Pharmacol 456: 99106.
  • Pertwee RG, Howlett AC, Abood ME, Alexander SPH, Di Marzo V, Elphick MR et al. (2010). International union of basic and clinical pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacol Rev 62: 588631.
  • Ross RA, Brockie HC, Stevenson LA, Murphy VL, Templeton F, Makriyannis A et al. (1999a). Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656 and AM630. Br J Pharmacol 126: 665672.
  • Ross RA, Gibson TM, Stevenson LA, Saha B, Crocker P, Razdan RK et al. (1999b). Structural determinants of the partial agonist-inverse agonist properties of 6′-azidohex-2′-yne-Δ8-tetrahydrocannabinol at cannabinoid receptors. Br J Pharmacol 128: 735743.
  • Rozenfeld R, Devi LA (2008). Regulation of CB1 cannabinoid receptor trafficking by the adaptor protein AP-3. FASEB J 22: 23112322.
  • Scandroglio P, Brusa R, Lozza G, Mancini I, Petro R, Reggiani A et al. (2010). Evaluation of cannabinoid receptor 2 and metabotropic glutamate receptor 1 functional responses using a cell impedance-based technology. J Biomol Screen 15: 12381247.
  • Thomas A, Stevenson LA, Wease KN, Price MR, Baillie G, Ross RA et al. (2005). Evidence that the plant cannabinoid Δ9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist. Br J Pharmacol 146: 917926.
  • Yao BB, Mukherjee S, Fan Y, Garrison TR, Daza AV, Grayson GK et al. (2006). In vitro pharmacological characterization of AM1241: a protean agonist at the cannabinoid CB2 receptor? Br J Pharmacol 149: 145154.